Zobrazeno 1 - 10
of 15 664
pro vyhledávání: ''
Autor:
Eliza A Hawkes, Jake Shortt, Greg Hapgood, Belinda A. Campbell, Dejan Radeski, Sze Ting Lee, Maya Latimer, Stephen Lade, Joshua W.D. Tobin, Henry Miles Prince, Bryone J. Kuss, D Purtill
Publikováno v:
Internal Medicine Journal. 52:1806-1817
Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous disease group accounting for 10% of non-Hodgkin lymphomas. PTCL patients have typically poorer outcomes compared to aggressive B-cell lymphomas. However, such outcomes are heavily dependen
Autor:
Stefania Tommasi, Letizia Porcelli, Roberta Di Fonte, Simona De Summa, Rosanna Lacalamita, Amalia Azzariti, Brunella Pilato, Katia Danza, Simona Serratì
Publikováno v:
Molecular Oncology, Vol 16, Iss 4, Pp 904-920 (2022)
Vitamin D is used to reduce cancer risk and improve the outcome of cancer patients, but the vitamin D receptor (VDR; also known as the calcitriol receptor) pathway needs to be functionally intact to ensure the biological effects of circulating calcit
Autor:
Sarah J. Freemantle, Megan Tomlin, Khadeeja Shahid, Andrea K. Corbet, Aleyah Hattab, Emmanuel Bikorimana, Hannah Baldwin, Raya I. Boyd, Ratnakar Singh, Cliff Yerby, Doha Shokry, Zeeshan Fazal, Michael J. Spinella
Publikováno v:
Molecular Oncology, Vol 16, Iss 3, Pp 683-698 (2022)
Molecular Oncology
Molecular Oncology
Testicular germ cell tumors (TGCTs) are aggressive but sensitive to cisplatin‐based chemotherapy. Alternative therapies are needed for tumors refractory to cisplatin with hypomethylating agents providing one possibility. The mechanisms of cisplatin
Autor:
Jitsuo Usuda, Susumu Takeuchi, Kengo Nagashima, Noriko Motoi, Masahiro Seike, Jun Matsubayashi, Hideaki Shiraishi, Kazufumi Honda, Shun-ichi Watanabe, Rintaro Noro, Kaoru Kubota, Xue Meng, Tatsuya Inoue, Huang Wilber, Ayumi Kashiro, Tetsuya Okano, Yukihiro Yoshida, Shinobu Kunugi, Akihiko Gemma, Norihiko Ikeda
Publikováno v:
Cancer Science. 113:1002-1009
Although adjuvant tegafur/uracil (UFT) is recommended for patients with completely resected stage I non-small cell lung cancer (NSCLC) in Japan, only one-third of cases has received adjuvant chemotherapy according to real-world data. Therefore, robus
Autor:
Keisuke Watanabe, Yu Hara, Ayami Kaneko, Yoichi Tagami, Ho Namkoong, Nobuyuki Horita, Takeshi Kaneko, Nobuaki Kobayashi, Nobuhiko Fukuda, Kohei Somekawa
Publikováno v:
Thoracic Cancer, Vol 13, Iss 1, Pp 84-94 (2022)
Thoracic Cancer
Thoracic Cancer
Background Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related mortality worldwide. It is advisable to select the appropriate treatment based on characteristics of the cancer such as pathology, mutations, and programmed deat
Autor:
Ziping Wang, Tienan Yi, Yun Fan, Guangqiang Zhao, Guangfa Wang, Gongyan Chen, Yong Song, Aimin Zang, Wenxiu Yao, Kangsheng Gu, Junfeng Liu, Caicun Zhou, Guohua Yu, Jianxing He, Jianling Bai, Huijuan Wang, Da Jiang, Xiaochun Zhang, Xiaohua Hu, Jie Zhang, Liyan Jiang, Kai Chen, Jiuwei Cui, Wenmin Xie, Qisen Guo, Lihong Wu, Chunhong Hu, Xiaorong Dong, Yueyin Pan, Junling Li, Guojun Zhang, Nong Yang, Min Peng, Xiaohong Wu, Lu Yue, Jianping Xiong, Qin Shi, Weihong Zhao, Yuping Li, Wei Tan
Publikováno v:
Cancer Communications, Vol 42, Iss 1, Pp 3-16 (2022)
Cancer Communications
Cancer Communications
Background Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small‐scale study. Here, we conducted a multicenter, randomi
Publikováno v:
Thoracic Cancer, Vol 13, Iss 2, Pp 257-264 (2022)
Thoracic Cancer
Thoracic Cancer
Background This study aimed to evaluate the inhibitory effects and potential mechanisms of icotinib combined with antiangiogenic drugs on lung adenocarcinoma in vivo. Methods A total of 72 mouse xenograft models established with human lung adenocarci
Autor:
Wenbo Liu, Yi Li, Xin Nie, Xu Li, Ping Zhang, Ailing Li, Bin Ai, Liming Wang, Yifan Yang, Shuai Zhang, Xiaonan Wu, Jiangyong Yu
Publikováno v:
Thoracic Cancer, Vol 13, Iss 1, Pp 31-37 (2022)
Thoracic Cancer
Thoracic Cancer
Background The aim of this study was to estimate the efficacy and safety of bevacizumab combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in advanced non‐small cell lung cancer (NSCLC) patients. Methods We search
Autor:
Tadashi Yoshino, Naoya Nakamura, Misa Sakamoto, Tomoka Ikeda, Yuria Egusa, Yoshito Nishimura, Yasuharu Sato, Azusa Fujita, Misato Doi, Noriko Iwaki, Asami Nishikori, Midori Filiz Nishimura, Yuka Gion
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 417-432 (2022)
Cancer Medicine
Cancer Medicine
Background Most patients with methotrexate‐associated lymphoproliferative disorder (MTX‐LPD) show diffuse large B‐cell lymphoma (DLBCL) or classic Hodgkin lymphoma (CHL) types. Patients with MTX‐LPD often have spontaneous remission after MTX
Autor:
Joachim Weischenfeldt, Hans Skovgaard Poulsen, Petra Hamerlik, Olga Østrup, Christina Westmose Yde, Aidan Flynn, Jannick Brennum, Dorte Schou Nørøxe, Finn Cilius Nielsen, Ulrik Lassen, Jane Skjøth-Rasmussen
Publikováno v:
Molecular Oncology, Vol 16, Iss 1, Pp 206-218 (2022)
Molecular Oncology
Nørøxe, D S, Flynn, A, Yde, C W, Østrup, O, Cilius Nielsen, F, Skjøth-Rasmussen, J, Brennum, J, Hamerlik, P, Weischenfeldt, J, Skovgaard Poulsen, H & Lassen, U 2022, ' Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma : a prospective study ', Molecular Oncology, vol. 16, no. 1, pp. 206-218 . https://doi.org/10.1002/1878-0261.13015
Molecular Oncology
Nørøxe, D S, Flynn, A, Yde, C W, Østrup, O, Cilius Nielsen, F, Skjøth-Rasmussen, J, Brennum, J, Hamerlik, P, Weischenfeldt, J, Skovgaard Poulsen, H & Lassen, U 2022, ' Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma : a prospective study ', Molecular Oncology, vol. 16, no. 1, pp. 206-218 . https://doi.org/10.1002/1878-0261.13015
Treatment of glioblastoma (GBM) remains a challenging task, with limited treatment options, none offering a cure. Immune therapy has proven effective across different cancers with remarkable response rates. Tumor mutational burden (TMB) is a marker o